$SII

Sprott (NYSE:SII) Issues Earnings Results, Beats Estimates By $0.58 EPS

Sprott (NYSE:SII) reported Q4 EPS of $1.11, significantly beating consensus estimates of $0.53 by $0.58. The company also saw its Assets Under Management (AUM) surge to $70.1 billion by February 2026, driven by strong inflows into precious metal trusts and ETFs. Despite missing revenue expectations, the stock price jumped approximately 10% following the earnings release.

Original reporting
MarketBeat · MarketBeat
Published Feb 21, 2026, 2:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 21, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sprott (NYSE:SII) Issues Earnings Results, Beats Estimates By $0.58 EPS — source image
Decision brief

The 30-second read

$SIIBullishHigh
01

Why it matters

The earnings surprise and AUM increase suggest improved investor confidence and sector strength, likely supporting the stock price in the near term.

02

Market read

The positive earnings and AUM growth reinforce the bullish outlook for Sprott and related sectors, with potential spillover effects into precious metals markets.

03

What to watch

Potential market correction or sector rotation could dampen gains; AUM growth may slow if market conditions change.

Relevance 6/10Timing: immediate, following earnings release and market reaction.

Background

Sprott reported Q4 earnings with a significant EPS beat and notable AUM growth, driven by strong inflows into precious metal trusts and ETFs.

Company-level read

Ticker impact

$SIIBullishHigh confidence
Context

Primary focus of the news, significant earnings beat and AUM growth.

Expected impact

moderate increase in stock price (~10%) in the short term, potential for continued growth if momentum sustains.

Evidence & confidence

Earnings beat significantly, AUM growth signals investor confidence, and positive market reaction confirms short-term bullish trend.

Market effects

Positive outlook for asset management and precious metals sectors due to increased inflows and assets.

Primarily US-focused, but positive sentiment may influence global precious metals ETFs.

Moderate, as Sprott's growth could impact global precious metals investment trends.

Counterpoint

The earnings beat may be a short-term anomaly; upcoming quarters could reveal margin pressures or revenue slowdown.

Key entities

  • Sprott Inc.

    A global asset management firm specializing in precious metals and alternative investments.

  • Precious Metal Trusts

    Funds invested in physical precious metals like gold and silver, attracting inflows.

Related articles

$SIIMed

Sprott (SII) Q2 2026 Earnings Call Transcript

Sprott Asset Management, in its Q2 2026 earnings call, reported AUM of $55.6B at June 30, 2026, down from $65.1B on March 31. Average AUM rose to $63.9B. Net income was $34.3M and adjusted EBITDA $50.8M. Net redemptions were $0.4B, mainly from precious metals physical trusts. Sprott declared a $0.40 dividend per share.

$AMZNMed

Amazon’s $8B Nvidia Chip Leaseback Deal [2026]

Amazon is reportedly in talks to lease back $8B worth of Nvidia Grace Blackwell chips from a financing vehicle, moving them off its balance sheet. The deal, if finalized, would involve an SPV issuing debt to investors and leasing the chips back to Amazon for AWS data centers. Both companies have not confirmed the deal, and details are still under discussion. The structure is part of a broader trend of tech firms using off-balance-sheet financing for AI infrastructure.

$BACMed

Bank of America (BAC) Personal Retirement Strategy Tops $100 Billion In Assets

Bank of America (BAC) reports its Personal Retirement Strategy program has surpassed $100 billion in assets under management, driven by digital tools combining managed portfolios with personalized retirement planning. This milestone reflects strong client uptake and potential for fee-based revenue growth, aligning with the bank's broader digital engagement strategy.

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.